O. Landgren Et Al. , "Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study," BRITISH JOURNAL OF HAEMATOLOGY , vol.198, no.6, pp.988-993, 2022
Landgren, O. Et Al. 2022. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. BRITISH JOURNAL OF HAEMATOLOGY , vol.198, no.6 , 988-993.
Landgren, O., Weisel, K., Rosinol, L., Touzeau, C., Turgut, M., Hajek, R., ... Mollee, P.(2022). Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. BRITISH JOURNAL OF HAEMATOLOGY , vol.198, no.6, 988-993.
Landgren, Ola Et Al. "Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study," BRITISH JOURNAL OF HAEMATOLOGY , vol.198, no.6, 988-993, 2022
Landgren, Ola Et Al. "Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study." BRITISH JOURNAL OF HAEMATOLOGY , vol.198, no.6, pp.988-993, 2022
Landgren, O. Et Al. (2022) . "Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study." BRITISH JOURNAL OF HAEMATOLOGY , vol.198, no.6, pp.988-993.
@article{article, author={Ola Landgren Et Al. }, title={Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study}, journal={BRITISH JOURNAL OF HAEMATOLOGY}, year=2022, pages={988-993} }